Last call: Sign up for one-on-one mentoring in the #JCO Journals Lounge at #ASCO24 by tomorrow, May 24, at 11:59 PM ET. ➡️ brnw.ch/21wK4sC

🎧 In this JCO Precision Oncology Conversations podcast ep, host Rafeh Naqash, MD speaks w/ Christian Rolfo
about his #JCOPO publication, “Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment.” ➡️ brnw.ch/21wJLyN

Had a great discussion w/Rafeh Naqash, MD on these recent JCO Precision Oncology publications on Erdafitinib in #FGFR altered tumors Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine OU Health Stephenson Cancer Center OU Health The ASCO Post @ASCO

Thanks for the invite JCOPO and Dr. Naqash! #PrecisionMedicine #precisiononcology

The stream of publications and progress continues!
Out today in JCO Precision Oncology: Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets ascopubs.org/doi/10.1200/PO…
Another one from Erik Faber, MD, PhD and Caris Life Sciences GI Onc group.

Finally in print JCO Precision Oncology!
We highlight the role of ctDNA as a prognostic and predictive biomarker in patients with appendix cancer at two high-volume centers
ascopubs.org/doi/10.1200/PO…

Erika Belmont David Su Kiran Turaga John Paul Shen Michael White Ardaman Shergill

📣 Attending #ASCO24 ? Sign up for one-on-one mentoring in the JCO Journals Lounge! ➡️ brnw.ch/21wJII9

🎧 In this episode, Rafeh Naqash, MD speaks w/ Jun Gong
about his 2 #JCOPO pubs, 'Phase 2 Study of Erdafitinib in Patients with Tumors with FGFR Amplifications' & 'Phase 2 Study of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions' ➡️ brnw.ch/21wJCNo

Characterization of #BRAF Thr599dup mutation as a targetable driver mutation identified in lung adenocarcinoma.
JCO Precision Oncology #LCSM BrafBombers

ascopubs.org/doi/10.1200/PO…

I'm so pleased to share that work led by
Kathryn Ries Tringale on the 'Prognostic Implications of SCLC Transcriptional Subtyping for CNS Mets' is online at JCO Precision Oncology (ascopubs.org/doi/full/10.12…)!
Memorial Sloan Kettering Radiation Oncology
Memorial Sloan Kettering Cancer Center

#JCOPO article shows the clinical value of MSI testing as a screening tool to ID patients w/ higher likelihood of a germline etiology of tumor development is underutilized w/ need to raise awareness of the value of #GeneticTesting for MSI-H tumors. ➡️ brnw.ch/21wJk3g

#JCOPO original report demonstrating how combining open standard HRD testing and RAD51 foci assay enhances prediction of PARPi sensitivity in #OvarianCancer . ➡️ brnw.ch/21wJjU9 #gyncsm

Secondary analysis of the ITACa randomized trial in #mCRC demonstrated that baseline inflammatory indexes such as #NLR have mostly a negative indirect effect on PFS with #bevacizumab having a protective effect in pts with high baseline NLR. ➡️ brnw.ch/21wJioR #crcsm

#JCOPO report showing #RET fusions may be a negative prognostic factor in patients w/ solid tumors w/ further emphasis for broader genomic testing since RET-specific TKIs for these tumors may improve outcomes beyond current standard of care options. ➡️ brnw.ch/21wJeRF

Data from AACR GENIE Biopharma Collaborative cohort show timing of NGS after diagnosis varied significantly by clinical characteristics suggesting applied researchers should examine the sensitivity of their findings to the timing of genomic sequencing. ➡️ brnw.ch/21wJdft

Across >2,500 pts w/ #mNSCLC , timely CGP before 1L initiation w/ increased targeted therapy use decreased expenditure on ICPIs among ALK/EGFR/RET/ROS1 driver-positive pts supporting importance of timely CGP to inform optimal 1L therapy selection. ➡️ brnw.ch/21wJawy #NSCLC

Read about TARGET, a randomized non-inferiority trial to compare pretest genetic education via a webtool for noninferiority to traditional genetic counseling (GC) in patients with #ProstateCancer (PCA). ➡️ brnw.ch/21wJ86I Stacy Loeb, MD Veda Giri #pcsm

#JCOPO article highlighting that the B-cell signature significantly shapes the overall tumor gene expression profile and influences patient prognosis in ER-positive #breastcancer . ➡️ brnw.ch/21wJ5o8 #bcsm

#ctDNA analysis of palbociclib-treated patients with metastatic #BreastCancer in the TREnd trial revealed an independent prognostic role of ESR1 mutations. ➡️ brnw.ch/21wJ3bB #mBC

1/2 Dual publication JCO Precision Oncology National Cancer Institute ECOG-ACRIN Cancer Research Group NCI-MATCH Subprotocol K2 positive PhII trial ➡️ activity of #Erdafitinib in treatment-refractory tumors w/ #FGFR1 -3 mutations or fusions, adding to evid for potential tumor agnostic indication?

ascopubs.org/doi/10.1200/PO…

OncoAlert

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2 | JCO Precision Oncology Jun Gong ascopubs.org/doi/10.1200/PO…